Dr. Lal PathLabs (LALPATHLAB) | Stock Overview & Key Data
Dr. Lal PathLabs Performance Comparison
Stock Range
Today's Range
Low: ₹3,170.00
High: ₹3,223.80
on August 8, 2025
52 Week Range
Low: ₹2,293.55
High: ₹3,653.95
on March 3, 2025
on October 10, 2024
All-Time High: ₹4,245.50 on September 13, 2021
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR268.1B
EPS
61.61
P/E Ratio (TTM)
52.15
Forward P/E
109.36
P/B Ratio
12.33
PEG Ratio
109.36
Div. Yield
0.93%
ROE
22.08%
Beta
0.081
Debt to Equity
7.14
Financial Highlights
Profitability
Gross Margin
66.99%
Operating Margin
23.54%
Profit Margin
20.29%
Returns and Earnings
Return on Assets (TTM)
17.93%
Return on Equity (TTM)
22.08%
EBITDA
INR8.2B
Net Income (TTM)
INR5.1B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR303.39
Quarterly Revenue Growth (YoY)
11.30%
Quarterly Earnings Growth (YoY)
24.40%
Dividend Information
Last 12-Month Dividend
₹30.00
Current Dividend Yield
0.93%
3-Year Average Dividend Yield
0.28%
3-Year Average Annual Dividend
₹20.00
3-Year Total Dividends
₹60.00
Ex-Dividend Date
August 6, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Dr. Lal PathLabs LALPATHLAB | 268.13B Large-cap | 0.41% | 10.77% | 14.95% | 15.06% | 4.50% | -0.66% | 30.89% | 71.26% |
| Syngene SYNGENE | 280.43B Large-cap | -6.83% | 3.58% | 7.29% | -11.01% | -25.48% | -22.04% | 10.74% | 31.92% |
| Sai Life Sciences SAILIFE | 165.96B Mid-cap | 5.06% | 5.26% | 17.03% | 15.41% | 9.22% | 17.66% | 17.66% | 17.66% |
| Vijaya Diagnostic VIJAYA | 110.12B Mid-cap | -2.67% | 5.23% | 5.45% | -3.97% | -0.79% | 27.14% | 196.35% | 68.17% |
| Metropolis METROPOLIS | 103.34B Mid-cap | -1.44% | 7.63% | 20.76% | 11.75% | -2.34% | -2.41% | 35.43% | 19.95% |
| Thyrocare THYROCARE | 71.34B Mid-cap | 1.26% | 25.18% | 47.77% | 71.98% | 45.08% | 65.86% | 115.09% | 89.72% |
Ownership & Short Interest
Insider Ownership
56.60%
Institutional Ownership
30.99%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
128K
Average 90-Day Volume
154K
Dr. Lal PathLabs Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Dr. Lal PathLabs would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is LALPATHLAB's 52-week high and low?
- In the last 52 weeks, Dr. Lal PathLabs reached a high of ₹3,653.95 (on October 10, 2024) and a low of ₹2,293.55 (on March 3, 2025).
- What is the market cap and P/E ratio for LALPATHLAB?
- Curious about Dr. Lal PathLabs's size and valuation? Its market capitalization stands at 268.13B. When it comes to valuation, the P/E ratio (trailing twelve months) is 52.15, and the forward P/E (looking ahead) is 109.36.
- Does LALPATHLAB pay dividends? If so, what's the yield?
- Yes, Dr. Lal PathLabs is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.93%, and the company has paid an average of ₹20.00 per share annually over the past 3 years.
- Who are Dr. Lal PathLabs's main competitors or similar companies to consider before investing?
When looking at Dr. Lal PathLabs, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Syngene
SYNGENE280.43B Healthcare Diagnostics & Research -22.04% 10.74% Sai Life Sciences
SAILIFE165.96B Healthcare Diagnostics & Research 17.66% 17.66% Vijaya Diagnostic
VIJAYA110.12B Healthcare Diagnostics & Research 27.14% 196.35% Metropolis
METROPOLIS103.34B Healthcare Diagnostics & Research -2.41% 35.43% Thyrocare
THYROCARE71.34B Healthcare Diagnostics & Research 65.86% 115.09% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Dr. Lal PathLabs Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Dr. Lal PathLabs's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 22.08%, the Debt to Equity ratio from the most recent quarter is 7.14, and its Gross Profit Margin stands at 66.99%.
- What is the recent revenue and earnings growth for LALPATHLAB?
- Looking at Dr. Lal PathLabs's growth, its revenue over the trailing twelve months (TTM) was INR25B. Compared to the same quarter last year (YoY), quarterly revenue grew by 11.30%, and quarterly earnings saw a YoY growth of 24.40%.
- How much of LALPATHLAB stock is held by insiders and institutions?
- Wondering who owns Dr. Lal PathLabs stock? Company insiders (like executives and directors) hold about 56.60% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 30.99%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.